136 related articles for article (PubMed ID: 37689127)
1. Antiresorptive agent-related osteonecrosis of the jaw risk in cancer patients before bone-modifying agent therapy: A retrospective study of 511 patients.
Kanno C; Kojima M; Tezuka Y; Yaginuma S; Kanaya Y; Kaneko T
Bone; 2023 Dec; 177():116892. PubMed ID: 37689127
[TBL] [Abstract][Full Text] [Related]
2. Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) in urological malignancies: a multi-center retrospective study.
Sakai Y; Shindo T; Sato S; Takahashi A; Kunishima Y; Kato R; Itoh N; Okada M; Tachiki H; Taguchi K; Takayanagi A; Hotta H; Horita H; Matsukawa M; Matsuki M; Nishiyama K; Miyazaki A; Hashimoto K; Tanaka T; Masumori N
J Bone Miner Metab; 2021 Jul; 39(4):661-667. PubMed ID: 33704573
[TBL] [Abstract][Full Text] [Related]
3. Incidence and Risk of Anti-Resorptive Agent-Related Osteonecrosis of the Jaw after Tooth Extraction: A Retrospective Study.
Shimizu R; Sukegawa S; Sukegawa Y; Hasegawa K; Ono S; Nakamura T; Fujimura A; Fujisawa A; Nakano K; Takabatake K; Kawai H; Nagatsuka H; Furuki Y
Healthcare (Basel); 2022 Jul; 10(7):. PubMed ID: 35885858
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease.
Fujieda Y; Doi M; Asaka T; Ota M; Hisada R; Ohnishi N; Kono M; Kameda H; Nakazawa D; Kato M; Amengual O; Takahata M; Yasuda S; Kitagawa Y; Atsumi T
J Bone Miner Metab; 2020 Jul; 38(4):581-588. PubMed ID: 32076874
[TBL] [Abstract][Full Text] [Related]
5. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.
Hasegawa T; Hayashida S; Kondo E; Takeda Y; Miyamoto H; Kawaoka Y; Ueda N; Iwata E; Nakahara H; Kobayashi M; Soutome S; Yamada SI; Tojyo I; Kojima Y; Umeda M; Fujita S; Kurita H; Shibuya Y; Kirita T; Komori T;
Osteoporos Int; 2019 Jan; 30(1):231-239. PubMed ID: 30406309
[TBL] [Abstract][Full Text] [Related]
6. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
Nakai Y; Kanaki T; Yamamoto A; Tanaka R; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Ishibashi M; Nishimura K
J Bone Miner Metab; 2021 Mar; 39(2):295-301. PubMed ID: 32886176
[TBL] [Abstract][Full Text] [Related]
7. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
Shibahara T
Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
[TBL] [Abstract][Full Text] [Related]
8. Survey of the association between tooth extraction and development of medication-related osteonecrosis of the jaw in patients undergoing cancer treatment with bone-modifying agents.
Nozawa-Kobayashi M; Sakuma H; Kanemaru H; Kurokawa A; Soga M; Yamashita M; Niimi K; Kobayashi T
Oral Maxillofac Surg; 2024 Jun; 28(2):849-857. PubMed ID: 38296902
[TBL] [Abstract][Full Text] [Related]
9. Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents?
Ueda N; Nakashima C; Aoki K; Shimotsuji H; Nakaue K; Yoshioka H; Kurokawa S; Imai Y; Kirita T
Clin Oral Investig; 2021 May; 25(5):3087-3093. PubMed ID: 33057886
[TBL] [Abstract][Full Text] [Related]
10. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
11. Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients.
Soutome S; Otsuru M; Hayashida S; Murata M; Yanamoto S; Sawada S; Kojima Y; Funahara M; Iwai H; Umeda M; Saito T
Sci Rep; 2021 Aug; 11(1):17226. PubMed ID: 34446755
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for dental findings of the development of medication-related osteonecrosis of the jaw: Investigation of 3734 teeth in cancer patients receiving high dose antiresorptive agents.
Otsuru M; Fujiki Y; Soutome S; Nakamura N; Miyoshi T; Naruse T; Ohnuma M; Hotokezaka Y; Rokutanda S; Umeda M
J Dent Sci; 2024 Jan; 19(1):203-210. PubMed ID: 38303840
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Preventive Treatment Protocols for Patients under Antiresorptive Therapy Undergoing Tooth Extraction at a Swiss University Clinic.
Pick E; Leuenberger N; Kuster I; Stutzmann NS; Stadlinger B; Valdec S
Int J Environ Res Public Health; 2021 Sep; 18(18):. PubMed ID: 34574862
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Periodontal Space Widening in Patients with Antiresorptive Drug-related Osteonecrosis of the Jaws (ARONJ) on Panoramic Radiographs.
Assaf AT; Amberg V; Smeets R; Wikner J; Hanken H; Semmusch J; Ewald F; Rashad A; Friedrich RE
Anticancer Res; 2018 Sep; 38(9):5305-5314. PubMed ID: 30194182
[TBL] [Abstract][Full Text] [Related]
15. Anti-VEGFR therapy is one of the healing inhibitors of antiresorptive-related osteonecrosis of the jaw.
Kanno C; Kaneko T; Endo M; Kitabatake T; Sakuma T; Kanaya Y; Watanabe Y; Hasegawa H
J Bone Miner Metab; 2021 May; 39(3):423-429. PubMed ID: 33196901
[TBL] [Abstract][Full Text] [Related]
16. Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries.
Taguchi A; Shiraki M; Morrison A; Khan AA
Osteoporos Sarcopenia; 2017 Jun; 3(2):64-74. PubMed ID: 30775507
[TBL] [Abstract][Full Text] [Related]
17. Clinical risk factors for severity and prognosis of antiresorptive agent-related osteonecrosis of the jaw: a retrospective observational study.
Nashi M; Hirai T; Iwamoto T; Takenobu T
J Bone Miner Metab; 2022 Nov; 40(6):1014-1020. PubMed ID: 36166107
[TBL] [Abstract][Full Text] [Related]
18. Single-center analysis of antiresorptive agent-related osteonecrosis of the jaw in lung cancer patients.
Okamura M; Fujita K; Yamamoto Y; Kanai O; Nakatani K; Horimoto K; Hashimoto M; Sawai S; Shimosato M; Yoshida K; Mio T
Asia Pac J Clin Oncol; 2020 Dec; 16(6):380-384. PubMed ID: 32893984
[TBL] [Abstract][Full Text] [Related]
19. Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents.
Tohashi K; Nakabayashi M; Kodani I; Kidani K; Ryoke K
Yonago Acta Med; 2016 Mar; 59(1):45-53. PubMed ID: 27046950
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: A subgroup analysis by disease stage.
Watanabe T; Asai K; Fukuhara S; Uozumi R; Bessho K
PLoS One; 2021; 16(1):e0244859. PubMed ID: 33395446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
